

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6964663
<b>Application Number:</b>	10531560
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3534
<b>Title of Invention:</b>	TREATMENT OF OSTEOARTHRITIS
<b>First Named Inventor/Applicant Name:</b>	Ian Alexander Shiels
<b>Customer Number:</b>	27683
<b>Filer:</b>	Mark D. Moore/Marty Miles
<b>Filer Authorized By:</b>	Mark D. Moore
<b>Attorney Docket Number:</b>	36672.6
<b>Receipt Date:</b>	05-FEB-2010
<b>Filing Date:</b>	27-JAN-2006
<b>Time Stamp:</b>	23:18:46
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	13021
Deposit Account	081394
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	36672_6_RCE.pdf	769798 781e0f9d65f1c572a13d13f57ecc280699f9c48b	no	3
<b>Warnings:</b>					
<b>Information:</b>					
2	Amendment Submitted/Entered with Filing of CPA/RCE	36672_RCE_Accompany.pdf	2320837 2833a7a7b4ba95d81c5941e8c5eb493d5a766421619	no	58
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	NPL_Anaya_Pulmonary_Involvement.PDF	229704 1717c33162f43806528eb2d32747fb7193ccafe	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	NPL_Arumugam_A_Small_Molecule_C5a.PDF	1962457 ca6d28170689083ea53c75c0e8c77b7ae903308	no	9
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	NPL_Arumugam_Protective_Effects.PDF	1864996 1c6d2f9e80aa71775d65698c811a59c7db3800e7	no	8
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	NPL_Baskaran_Dynamics_of_Tissue.PDF	2100933 05795cf6a7165a3b301d4f5e6b85e23a781929d2	no	9
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	NPL_Beams.pdf	2094646 3d3d85ec2adb5ada1ee7e7972f5d7312501736	no	12
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	NPL_Benoit_Studies_On_Sensitivity.PDF	1576276 c09c1cc081d6d44f0194e52b623165f81f2f3734	no	8
<b>Warnings:</b>					
<b>Information:</b>					

9	NPL Documents	NPL_Bernadelli_et al_Trends_and_Perspectives.PDF	4230050 5c56530bb65da786c0ff6a7a2628c95c5a1947b	no	21
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	NPL_Bertrand_CCR3_Blockade.PDF	2027274 d49f13766dacc2753d8f66dc5a7a7f6d4d	no	10
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	NPL_Bodansky_Introduction_of_Amine.PDF	2860861 a5e059d2c7e3d5a78c625d8b6a7a615c8b72a7	no	19
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	NPL_Brady_Large_Scale.PDF	1851584 c72123d4e74f6d5d11d6d83d6dc7c5d1bbd7c	no	6
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	NPL_Cain_Modulation_of_LigandSelectivity.PDF	1622694 d307398374ac49569a9c20bcb88382c115cd00d	no	9
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	NPL_Chan_Basic_Procedures.PDF	4445833 40113c1e59d6164d5018c17668153c160f5015	no	19
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	NPL_Cheng_Trends_Perspectives_1995.PDF	3102513 4f78c4c4b65a5a975569923cb4b4b0b095b5d81	no	18
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	NPL_Dinarelo.pdf	329251 7c3409c3c5d608b28fce0828ce4bcb6edf5d5d	no	5
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	NPL_Diop.pdf	1929873 42a7ab110717c17d66c914b0f55d82b26d6b778	no	10
<b>Warnings:</b>					
<b>Information:</b>					

18	NPL Documents	NPL_Fields_Solid_Phase.PDF	7371926 d78bd42f12b7536a28a6975e42d7ad15d11b97	no	28
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	NPL_Fukunaga_A_Novel.PDF	1840654 388b3dd946d10dc3c3f3ca0115d85cd0160ff	no	9
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	NPL_Galatis_Trends_and_Perspectives.PDF	3732280 2efc0b3485384282c2d43c4402d12e980c3389c	no	22
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	NPL_Gao_RecentAdvances.PDF	586436 3414018c0b28a2c805072a1573327a716bb1e4f	no	14
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	NPL_Gaudilliere_Trends_Perspectives_2001.PDF	4539770 2e981118c1c007ad2d40025d4f8ac2073d404d	no	26
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	NPL_Gaudilliere_Trends_Perspectives_2000.PDF	4293100 2732683901ad2a3afcd8c82b98530c94a1f6dbb	no	26
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	NPL_Harkin.pdf	1925050 0d6a0b0418ecac32ad614b276d28137d8a1610a6	no	11
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	NPL_Haynes_Inhibition.PDF	980028 549f601d825672694f5d81044ce6028b61c695ec	no	5
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	NPL_Heller.pdf	2363092 37a28d5f8ec2d07801b0ff7cdcc030045c158	no	10
<b>Warnings:</b>					
<b>Information:</b>					

27	NPL Documents	NPL_Ikeda_Simvastatin_Attenuates.PDF	1277713 2b666ed315f348223d4f5d3e49473ea3e0f6699b	no	7
Warnings:					
Information:					
28	NPL Documents	NPL_Johnson_Heterotrimeric.PDF	2707250 0f6d681b7947489fdec279e91ea104470ee76291	no	11
Warnings:					
Information:					
29	NPL Documents	NPL_Makrides_Therapeutic_Inhibition.PDF	7370618 3ef7db47a1f64a6b8f0e263a2e149cc59c1328042	no	29
Warnings:					
Information:					
30	NPL Documents	NPL_Morikis.pdf	2089339 ed7d6782c1005617abf0e444ce41028b2b0f698d	no	11
Warnings:					
Information:					
31	NPL Documents	NPL_Morris_Hapten_Induces.PDF	2801940 b725eca6e87303d4913d81e0fc2055ebbc31739	no	9
Warnings:					
Information:					
32	NPL Documents	NPL_Owen_Chemokine_Receptors.PDF	2214247 5c81ad5e0207b068990e4474e6f13db259f1de4	no	10
Warnings:					
Information:					
33	NPL Documents	NPL_Paczkowski_pharmacological_Characterization.PDF	1468864 1002f62a6f60370150a31ca7450f14b7bd035007	no	6
Warnings:					
Information:					
34	NPL Documents	NPL_Piccolo_Chemotactic_Mediator.PDF	1303087 9bc04d9a775b21b7a2265de57192759f434724e4	no	7
Warnings:					
Information:					
35	NPL Documents	NPL_Reid.pdf	237719 bd7dc62e4b37436287f55614c3d3b0e04026c51	no	2
Warnings:					
Information:					

36	NPL Documents	NPL_Roschmann_Pulmonary_Fibrosis.PDF	206322 813c1c286a668a526c7b3998ba0ef52718e75eba	no	1
<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	NPL_Schmid_Requirement_for_PDF	1365219 2512801e81b7c1b73c833c495c0158c094e5d48	no	6
<b>Warnings:</b>					
<b>Information:</b>					
38	NPL Documents	NPL_Schuda_A_Short.PDF	935232 99810252ac13773eef8f4ef9971f04bf23a538d98	no	3
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	NPL_Short_Effects_of.PDF	818646 a10b786d8033ae482c8b7771f918ba10c4195f9798	no	4
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	NPL_Smith_Organic_Synthesis.PDF	598081 5ef388e4262658f912174ae228415c82e051ae05	no	5
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	NPL_Steinauer_Studies_on.PDF	857561 d27d2514badcc26c5645e05958f91581aefec64	no	4
<b>Warnings:</b>					
<b>Information:</b>					
42	NPL Documents	NPL_Stewart_Current_Therapy.PDF	1122137 4a3c94ca60b6ad1c76c47d47ad6295e6232412a	no	5
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	NPL_Strachan_Inhibition_of_PDF	1915686 7bec6d8da294b08b7aaf7053ccc6f5d318c73d2	no	9
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	NPL_Strietter_Effects_of.PDF	490293 c3983c9d1242978f91956913c1375ff6d141d5e	no	2
<b>Warnings:</b>					
<b>Information:</b>					

45	NPL Documents	NPL_Szebeni.pdf	2134014 18803a6dc7a8f2b6451aef02b2f03c489c415e2cf	no	9
Warnings:					
Information:					
46	NPL Documents	NPL_Taylor_Regulations_of_the.PDF	1974301 e2698a5c1ca2988bc2e9a88f30967c4d74e27	no	10
Warnings:					
Information:					
47	NPL Documents	NPL_Toulouse.pdf	1622761 5b5a5fa99b2286079d7aef8f25c357d4443f5ec6	no	7
Warnings:					
Information:					
48	NPL Documents	NPL_VanaAssche_Emerging_Drugs.PDF	2369716 Sec73678befcc28b905907e02126ef30371679dd	no	11
Warnings:					
Information:					
49	NPL Documents	NPL_Wong_Small_Molecular.PDF	2179937 528b837252475d8b899ed8b5d864107597a5d	no	9
Warnings:					
Information:					
50	NPL Documents	NPL_Woodruff_Species_Dependence.PDF	1107265 0c488a49c2159176175d01a0893877332b4e9d7	no	7
Warnings:					
Information:					
51	NPL Documents	NPL_Mita.pdf	2129518 31cd4b01d276cc1676a2b9f08a83c5e6b7a649	no	10
Warnings:					
Information:					
52	NPL Documents	NPL_Piccolo_Role_of.PDF	2825893 bc9991a7a05210aba4c0228811c5d8d006960418	no	15
Warnings:					
Information:					
53	Information Disclosure Statement (IDS) Filed (SB/08)	36672_6_IDS1.pdf	1102098 8868d4d7c728fc083d4d0750c91abef42cbee4fe	no	8
Warnings:					
Information:					

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

54	Fee Worksheet (PTO-875)	fee-info.pdf	30002 b3472b6d71a64661ca0d43808ff1a8f910432	no	2
----	-------------------------	--------------	--	----	---

**Warnings:**

**Information:**

**Total Files Size (in bytes):** 110207375

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.